Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsMargaret E. Callahan, Thomas M. Folks, Paul Sandstrom, Shambavi Subbarao, Jennifer Brown, Walid Heneine, William M. Switzer
Estimating the term…
The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
A method for detecting a spumavirus infection, comprising, contacting a sample of nucleic acids with a probe comprising a sequence specific for SFVHu-1.
A method for detecting a spumavirus infection, comprising, contacting a sample of nucleic acids with a probe comprising a sequence of SFVHu-1, wherein the sequence is specific for a virus which comprises a polymerase gene with greater than 87.5% sequence identity to the polymerase gene of SFVHu-1.
A method for detecting a spumavirus infection, comprising, contacting a sample of nucleic acids with a probe comprising a sequence of SFVHu-1, wherein the probe does not consist of a sequence of SFV-3.
Dependencies are inferred from the claim text.